AAPS PharmSciTech

, 5:96 | Cite as

Pulmonary absorption of liposomal levonorgestrel

Article

Abstract

The purpose of these studies was to achieve desired bioavailability after pulmonary administration of Levonorgestrel (LN) and to provide prolonged effective concentration of the drug in plasma and to reduce reported side effects of orally administered drug. The plain drug suspension, physical mixture (plain drug with liposomal constituents), and drug-encapsulated liposomes containing 10 μg of drug were instilled intratracheally in rats. Similarly, 10-μg drug suspension (LO) was administered orally. The blood samples were withdrawn at specific time intervals and were subjected to LN analysis by spectrofluorimetric technique. The plasma drug concentration data of both the treatments were plotted, and pharmacokinetics data were calculated and compared with that of oral administration. Percentage relative bioavailability (F*) of 97.6% 98.6%, and 109.9% were observed after pulmonary administration of plain drug formulation (LP1), physical mixture (plain drug along with constituents of liposomes [LP2], and liposomal (LP3) formulations of the drug, respectively. Following oral administration, Cmax of 14.4±0.6 ng/mL was observed at 2.1±0.2 hours followed by subtherapeutic concentration beyond 30±0.2 hours, while after pulmonary administration of LP1, LP2, and LP3 formulations, Cmax of 4.4±0.4 ng/mL, 4.2±0.5 ng/mL, and 4.4±0.6 ng/ML were observed at 6.0±0.2 hours, 7.0±0.2 hours, and 6.8±0.2 hours, respectively, followed by maintenance of effective plasma drug concentration up to 60±2 hours. These studies demonstrate superiority of pulmonary drug delivery with regards to maintenance of effective therapeutic concentration of the LN in the plasma over a period of 6 to 60 hours. Hence, the pulmonary delivery is expected to reduce frequency of dosing and systemic side effects associated with oral administration of LN.

References

  1. 1.
    Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens.N Engl J Med. 2002;346:340–352.CrossRefPubMedGoogle Scholar
  2. 2.
    Mueck AO, Seeger H, Graser T, Oettel M, Lippert TH. The effects of postmenopausal hormone replacement therapy and oral contraceptives on the endogenous estradiol metabolism.Horm Metab Res. 2001;33:744–747.CrossRefPubMedGoogle Scholar
  3. 3.
    Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, Hollenberg PF. Effect of 17-alphaethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites.J Pharmacol Exp Ther. 2002;300:549–558.CrossRefPubMedGoogle Scholar
  4. 4.
    Ellison J, Thomson AJ, Greer IA, Walker ID. Drug points: apparent interaction between warfarin and levonorgestrel used for emergency contraception.BMJ. 2000;1321–1382.Google Scholar
  5. 5.
    Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.Lancet. 1999;354:2036–2040.CrossRefPubMedGoogle Scholar
  6. 6.
    McCann MF, Potter LS. Progestin-only oral contraception: A compre-hensive review.Contraception. 1994;50(6 suppl 1): S1–195.CrossRefPubMedGoogle Scholar
  7. 7.
    Vyas SP, Khar RK.Nasopulmonary Drug Delivery in Controlled Drug Delivery: Concept and Advances. Vallabh Prakashan, India: 2002;341–342.Google Scholar
  8. 8.
    Shek PN, Barber RF. Liposomes: a new generation of drug and vaccine carriers.Mol. Med. Canada. 1986;41:314–326.Google Scholar
  9. 9.
    Kimelberg HK, Mayhew EG. Properties and biological effects of liposomes and their uses in phamacology and toxicology.CRC Crit Rev Toxicol. 1978;6(1):25–79.CrossRefGoogle Scholar
  10. 10.
    Szoka F, Papahadjopoulos D. Liposomes: preparation and characterization. In: Knight CG, ed.Liposomes: From Physical Structure to Therapeutic Applications. New York, NY: Elsevier/North-Holland Biomedical Press, 1981:51–82.Google Scholar
  11. 11.
    Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: A critical review.Pharmacol Rev. 1984;36:277–336.PubMedGoogle Scholar
  12. 12.
    Knight CG.Liposomes: From Physical Structure to Therapeutic Application. New York, NY: Elsevier/North-Holland Biomedical Press, 1981.Google Scholar
  13. 13.
    Joshi MR, Misra AN. Dry powder inhalation of liposomal ketotifen fumarate: Formulation and characterization.Int J Pharm. 2001b;223:15–27.CrossRefPubMedGoogle Scholar
  14. 14.
    Enna SJ, Schanker LS. Absorption of drugs from the rat lung.Am J Physiol. 1972;223:1127–1231.Google Scholar
  15. 15.
    Andrew SM, Leo CF. Norgestrel. In: Florey K, ed.Analytical Profile of Drug Substances. Vol. 4 New York NY: Academic Press; 1975.Google Scholar
  16. 16.
    Gibaldi M, Perri D.Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker, 1982.Google Scholar
  17. 17.
    Anderson MW, Orton TC, Pickett RD, Eling TE. Accumulation of amines in the isolated perfused rabbit lung.J Pharmacol Exp Ther. 1974;189:456–466.PubMedGoogle Scholar
  18. 18.
    Suhara T, Sudo Y, Yoshida K, et al. Lung as reservoir for antidepressants in pharmacokinetics drug interactions.Lancet. 1998;351:332–335.CrossRefPubMedGoogle Scholar
  19. 19.
    Roerig DL, Kotrly KJ, Dawson CA, Ahlf SB, Gualtieri JF, Kampine JP. First-pass uptake of verapamil, diazepam, and thiopental in the human lung.Anesth Analg. 1989;69:451–466.CrossRefGoogle Scholar
  20. 20.
    Jorfeldt L, Lewis DH, Lofstrom JB, Post C. Lung uptake of lidocaine in healthy volunteers.Acta Anaesthesiol Scand. 1979;23:567–574.CrossRefPubMedGoogle Scholar
  21. 21.
    Dollery CT, Junod AF. Concentration of (±)-propranolol in isolated, perfused lungs of rat.Br J Pharmacol. 1976;57:67–71.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Juliano RL, McCullogh HN. Controlled delivery of an anti tumor drug: Localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system.J Pharmacol Exp Ther. 1980;214:381–388.PubMedGoogle Scholar
  23. 23.
    Shek PN, Jurima-Romet M. Lung uptake of liposome-entraped glutathione after intratracheal administration.J Pharm Pharmacol. 1991;43:6–10.CrossRefPubMedGoogle Scholar
  24. 24.
    Juliano RL, McCullogh HN. Controlled delivery of an anti tumor drug: Localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system.J Pharmacol Exp Ther. 1980,214:381–388.PubMedGoogle Scholar
  25. 25.
    Brown RA, Schanker LS. Absorption of aerosolized drugs from the rat lung.Drug Metab Dipos. 1983;11:355–360.Google Scholar
  26. 26.
    Schanker LS, Mitchell EW, Brown RA, Jr. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection.Drug Metab Dispos. 1986;14:79–88.PubMedGoogle Scholar
  27. 27.
    Brain JD, Knudson DE, Sorokin SP, Davis MA. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation.Environ Res. 1976;11:13–33.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2004

Authors and Affiliations

  1. 1.Pharmacy Department Faculty of Technology & Engineering KalabhavanM S University of BarodaVadodaraIndia

Personalised recommendations